NIH
Executive Summary
Seeks licensees for calanolide A or related anti-viral compounds for treatment of HIV infection via March 30 Federal Register notice. The compounds, derived from the tropical rain forest tree Calophyllum lanigerum, strongly inhibit HIV-1 replication in vitro, NIH says